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A B S T R A C T
Cryptococcal meningitis (CM) contributes signiﬁcantly to high early mortality in the setting of advanced HIV. In
resource poor settings, the current HIV disease management approach is focused on commencing antiretroviral
therapy (ART) on the same day of HIV diagnosis (‘Test and Treat’). The HIV program in Nigeria does not
currently provide CrAg screening for patients with newly diagnosed and advanced HIV disease. We report a case
of severe cryptococcal meningitis presenting following the commencement of ART. There is clear beneﬁt in the
early commencement of ART among HIV infected patients and to prevent patients lost to follow-up as aimed
with the ‘Test & Treat’ approach. However, this approach needs to be balanced against the risk of IRIS and its
associated morbidity and mortality when those patients are not being properly evaluated for opportunistic in-
fections being present without overt symptoms.
1. Introduction
Cryptococcal meningitis (CM) contributes signiﬁcantly to high early
mortality in the setting of advanced HIV [1,2] with 10–20% of HIV
associated deaths in Africa attributable to cryptococcosis [3]. It is es-
timated that Cryptococcus spp. is the causative organism in up to 63% of
meningitis cases among adults in Sub-Saharan Africa [3,4]. The global
prevalence of asymptomatic cryptococcal antigenaemia is 6% [5], but
various studies in Nigeria have shown a higher prevalence of crypto-
coccal antigenaemia among HIV patients ranging from 2.3 to 13.1%
[6,7]. The true incidence of CM in Nigeria is not known, however, a
study by Gomerep et al. conducted among HIV patients presenting with
features of meningitis found that 36% of conﬁrmed cases were due to
cryptococcal infection [8].
There is clear evidence to show that early commencement of anti-
retroviral therapy (ART) in HIV patients improves outcomes [9], and
reduces the incidence of AIDS deﬁning illnesses (including crypto-
coccosis) especially in Western countries [10]. The reduction of
cryptococcal infections in the setting of HIV within Sub-Saharan
countries has been less remarkable due to the high burden of HIV in-
fection coupled with late presentation of advanced disease, and low
ART coverage [11]. The situation is further compounded by high rates
of poverty, sub-standard living conditions and weak, over-burdened
and poorly funded health systems [12]. In resource poor settings, the
current approach is focused on commencing ART on the same day of
HIV diagnosis [13]. This is in the bid to reduce the progression of HIV
infection and overcome the high rates of loss to follow up due to long
laboratory turnaround times delaying the diagnosis commonly en-
countered in these settings.
The point of care cryptococcal antigen (CrAg) lateral ﬂow assay has
been proven to be a cost eﬀective tool in the detection of cryptococcal
antigenaemia allowing pre-emptive therapy in HIV infected patients
with severe immunosuppression [14]. In spite of this, the HIV program
in Nigeria does not provide CrAg screening in patients with newly di-
agnosed and advanced HIV. Consequently, newly diagnosed HIV pa-
tients are being commenced on ART on the same day of diagnosis
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without proper evaluation for infections like cryptococcosis, putting
them at risk of life-threatening immune reconstitution inﬂammatory
syndrome (IRIS) [15].
We report a case of severe cryptococcal meningitis presenting fol-
lowing the commencement of ART on the day a diagnosis of HIV was
made.
2. Case
A 52 year old business man, presented with 4 weeks history of fever
and headache, and a 1 week history of impaired vision.
Initially been treated for malaria, but with a poor response, he
presented at the peripheral hospital where he tested positive for HIV-1
antibodies and was commenced on ART consisting of tenofovir, lami-
vudine and efavirenz (TDF/3TC/EFV) the same day. Consequently, his
headache become worse and he developed visual disturbances, for
which a referral was made to our facility. At presentation (day 0), he
had low grade fever with no history of drenching sweats, signiﬁcant
weight loss, anorexia and headaches associated with projectile vo-
miting. He was noticed to have become increasingly restless requiring
restraint at home, and had complained of double and blurred vision
with subsequent visual loss. There was no history of seizures, no dif-
ferential limb weakness, and no history of preceding behavioral
changes. There was no history of cough, and review of other systems
was essentially normal. He was not previously known to be hyperten-
sive or diabetic, and had a history of occasional alcohol use, however no
previous tobacco use.
On examination he had a slightly elevated temperature (37.7 °C), an
elevated blood pressure (170/134mmHg) with a heart rate of 82/min.
Pallor, neck stiﬀness and a positive Kernig's sign, and a marked rest-
lessness was noticed. His Glasgow Coma Score was 12 (E-4, V-3, M-5).
There was photophobia, sluggishly reactive unequal pupils, with a right
lateral rectus palsy as well as asymmetrical right-sided facial weakness
aﬀecting the lower part of the face, corresponding to a left upper motor
neuron type facial nerve palsy, but was moving all limbs. Fundoscopy
showed papilloedema.
Blood cryptococcal antigen (CrAg) test (LFA) was positive. Brain
MRI was reported normal, and a lumbar puncture was performed. The
opening pressure was high as revealed by forceful jet of cerebrospinal
ﬂuid (CSF) (we had no access to manometers), slightly turbid, non-
bloody CSF which did not form strands on standing. Qualitative CSF
CrAg test was positive; however, we were unable to carry out quanti-
tative measurement of serum and CSF CrAg due to unavailability of this
test modality in our center. Gram stain revealed scanty pus cells with no
organisms seen, pleocytosis with 3680 lymphocytes/μL but nil neu-
trophils, elevated CSF protein of 1.07 g/L, CSF glucose of 2.2 mmol/L
(blood glucose 6.0 mmol/L), and CSF culture growing Cryptococcus
neoformans. The CSF gene Xpert test for tuberculous meningitis was
negative. HIV viral load of 1807 copies/mL (after 2 weeks on ART).
Due to initial unavailability of amphotericin B and ﬂucytosine, he
was commenced on monotherapy with intravenous ﬂuconazole
1200mg daily in 3 divided doses (day 1). Amphotericin B was even-
tually procured after 8 days of monotherapy with ﬂuconazole, and he
then received a combination of amphotericin B (0.7 mg/kg/day) and
ﬂuconazole (1200mg day in 3 divided doses) for another 2 weeks (day 9
to day 25). He underwent daily therapeutic lumbar punctures for the
initial four days of admission, each time draining about 15 mL of CSF
with satisfactory clinical response.
He received consolidation treatment (from day 26 onwards) con-
sisting of 800mg ﬂuconazole orally per day in 2 divided doses for 8
weeks, and is currently receiving maintenance phase treatment with
200mg of oral ﬂuconazole once daily. The patient has made sustained
clinical progress (day 165), with resolution of symptoms and reduction
of the blood pressure. He however has residual blindness, and the facial
nerve palsy is yet to completely resolve (see Figs. 1 and 2). He is still on
follow up at our clinic.
3. Discussion
This case highlights the drawback of the ‘Test & Treat’ approach; the
low level of awareness/index for suspicion for cryptococcal meningitis
among clinicians, the lack of a coordinated screening program for
asymptomatic cryptococcal infection among newly diagnosed HIV pa-
tients and poor access to recommended antifungal medication.
The ‘Test & Treat’ approach, which is a public health algorithm, has
clearly shown beneﬁt in overcoming delay, reducing loss to follow-up
commonly observed among newly diagnosed HIV-infected patients, and
reversing the progressive immunosuppression and development of new
opportunistic illnesses associated with HIV infection. The major draw-
back of the approach, especially where the implementation is not hol-
istic, is the development of life-threatening IRIS. In Nigeria, the delay in
the availability of CD4 cell counts during initial evaluation means that
patients with very low CD4+ T cell counts also commence ART on the
same day of treatment without the requisite evaluations/screening tests
that could be lifesaving.
This case also highlights the low level of awareness and low index of
suspicion among clinicians providing HIV care in Nigeria. Even though
the symptoms of headache and fever were prominent when the patient
initially presented to the initial hospital, those were not properly
Fig. 1. Forehead wrinkling and eyelid symmetry was preserved in the patient,
but he had asymmetry of the lower part of the face when he was asked to smile
and bare his teeth, corresponding to a left upper motor neuron facial nerve
palsy. This was still observable after completion of induction therapy with
amphotericin B and ﬂuconazole for 2 weeks.
Fig. 2. Forehead wrinkling and eyelid symmetry was preserved in the patient,
but an asymmetry of the lower part of the face was observed when he was asked
to smile and bare his teeth, corresponding to a left upper motor neuron facial
nerve palsy, still observed at 8 weeks since start of induction treatment (am-
photericin B and ﬂuconazole 1200 mg/d) followed by consolidation treatment
with oral ﬂuconazole (800 mg/d).
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evaluated prior to commencing ART. As such, his presentation was
likely a case of cryptococcal meningitis IRIS as evidenced by the ob-
served clinical deterioration after commencement of ART, the lym-
phocytosis and elevated protein in the CSF [15].
Current guidelines recommend screening all HIV infected patients
with CD4 cell counts< 100 cells/mm3 using CrAg LFA kits [16], which
have been found to be highly sensitive and speciﬁc, and cost eﬀective in
reducing the mortality of cryptococcal disease in HIV infected patients,
not to mention the added beneﬁt of preventing the occurrence of un-
masking IRIS among those starting ART. The COAT trial has clearly
demonstrated the beneﬁt of starting ART 4–6 weeks after the use of
antifungals in patients with cryptococcal meningitis [17].
Presently, there is no provision to routinely screen for crypto-
coccosis among HIV patients with advanced HIV disease in Nigeria.
Where CrAg testing is available, patients pay for the tests out of pocket.
In most cases however, they get prescribed low dose oral ﬂuconazole or
ART straight away. The WHO guidelines for the care of patients with
advanced HIV provides for the evaluation for opportunistic infections
prior to the start of ART [18]. This is geared towards reducing the
mortality associated with the occurrence of IRIS in the setting of im-
mune recovery [15]. Among patients who present with symptoms of
headache and fever, the availability of CrAg tests has simpliﬁed the
procedure for evaluating HIV infected patients at risk of cryptococcal
infection [19]. Patients identiﬁed with asymptomatic cryptococcal an-
tigenaemia are pre-emptively treated with oral ﬂuconazole. Even
though primary prophylaxis with low dose oral ﬂuconazole among HIV
may reduce mortality from cryptococcosis in patients without me-
ningitis [1], there are unintended consequences, including increasing
resistance of isolates to ﬂuconazole and high costs [20].
There is therefore an urgent need to proactively institute routine
screening for the detection of asymptomatic cryptococcal antigenaemia
among at risk HIV infected patients who are receiving care within the
Nigerian HIV treatment program. This should be implemented along
with provision of point of care test kits for measurement of baseline
CD4 cell counts to better identify at risk patients. Lastly, more eﬀort is
needed to increase the awareness of the Nigerian clinician about the
risk and complications of cryptococcal meningitis in HIV.
In conclusion, there is clear beneﬁt in the early commencement of
ART among HIV infected patients and to prevent patients lost to follow-
up as aimed with the ‘Test & Treat’ approach. Nevertheless, this ap-
proach needs to be balanced against the risk of IRIS and its associated
morbidity and mortality when those patients are not being properly
evaluated for opportunistic infections being present without overt
symptoms. The ‘Test & Treat’ approach needs to be optimized with
point-of-care screening tests being implemented to treat asymptomatic
cryptococcal infections in newly diagnosed HIV infected patients.
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